The Pharma Ad You Hate Isn't For You

Some diseases have a champion. The rest have a commercial that has to find people before they know they need it.

I watched the Emmys last month from a hotel room, on linear TV, on the first night of Fierce Pharma Week. I counted fifteen pharma ads over the course of the broadcast. For those watching who aren't healthcare marketers or advertising executives, most Americans probably had similar thoughts: "there are too many pharma ads."

Then Michael J. Fox came onstage in a wheelchair to accept the Bob Hope Humanitarian Award. He talked about first being diagnosed with Parkinson's Disease in his twenties and hiding it, because he was afraid of what it would do to his work and to his relationship with an audience. The room stood up before he spoke and again after.

Now imagine a newly approved Parkinson's therapy running a sixty-second spot in the first break after that speech. Nobody in that room calls it another pharma ad. Nobody posts about the clutter.

Fame gets handed out almost at random

Parkinson's has a face, and has had one since 1998. It has a foundation that has put more than $3 billion into research, and an advocate who spent three decades making the disease familiar to people who will never have it.

Plaque psoriasis doesn't have that. Neither does COPD, or ulcerative colitis, or hidradenitis suppurativa, or vitiligo. These are serious conditions. Several are progressive, and several carry a social stigma that patients routinely describe as harder to live with than the symptoms. None of them has a Michael J. Fox.

So the public's tolerance for an ad tracks the fame of the disease rather than its severity. That ranking wasn't set by medicine. It was set by who happened to get sick, when, and whether they were already on television.

For most conditions, the commercial is the advocacy

Here's the part I find genuinely uncomfortable, and I think the industry should too. For a disease with no public champion, a sixty-second ad is the only mass communication that condition will ever get. Not the leading form. The only form.

That's a strange way to run public health education, and the honest case against it is strong. A company with a product to sell is not a neutral narrator. The risk disclosure gets read at a pace nobody absorbs while the imagery does the actual persuading. Critics who say this is self-interested storytelling are correct, because it is.

But the alternative being offered isn't a better narrator. It's silence. And silence isn't neutral. Silence is how a condition stays invisible, how people go undiagnosed for years, how somebody keeps believing their symptoms are a personal failing rather than something with a name and a treatment.

The industry already half knows this. Two of the fifteen ads I counted were unbranded, disease-state awareness ads, including Novartis running "Your Attention Please" and Tarsus running "Blame the Mites." There's nothing to buy at the end of those spots. The entire media investment goes toward educating the public, en masse. That's advocacy with a budget behind it, and it's the most undervalued line in pharma marketing.

Television is the last place you see something that isn't for you

This is the part I'd most want the media side of this business to sit with.

Search and social give back what someone already knew to ask for. The feed is a mirror. It's very good at serving a person who has a diagnosis and a question, and structurally incapable of reaching the person who has symptoms and no vocabulary for them. Nobody searches for a drug name they've never heard of. Nobody searches for a condition they haven't been told they have.

Broadcast works the other way, almost by accident. It's a window. The same property that makes an ad irrelevant to most of the room is exactly the property that lets it find the one person who didn't know to look, or the daughter watching with her father who hears a list of symptoms and recognizes them.

The annoyance and the value are the same mechanism. You don't get to keep one and delete the other.

This year's Emmys broadcast is all the more significant after this week's announcement that beginning in 2027, the Emmys will be streaming live on Prime Video. Is this fair to viewers to put the pinnacle of television awards behind a paywall?

Probably not. But it's akin to the same trend in which how Americans consume content is transmitted through systems designed to show them things they already want (i.e., echo chambers). While this personalization and precision has offered immense benefits to advertisers and consumers, the added value of stumbling upon an ad never meant for you keeps getting smaller. And it's those exact moments that are indispensable for pharma advertisers looking to reach patients or their loved ones before they may ever know they're needed.

Michael J. Fox accepted that award on broadcast's last Emmys night, for making a disease visible to millions of people who will never be diagnosed with it. That kind of visibility used to be a byproduct of how television worked. It's becoming something a company has to decide to pay for on purpose. I'm not sure anyone in this industry currently considers that their job, and I'd like to know who does.